Dublin, January 14, 2020 (GLOBE NEWSWIRE) – The report “Global market for women’s health diagnosis 2019-2025” has been added to ResearchAndMarkets.com’s offering.
The global market for women’s health diagnosis is growing significantly during the forecast period.
This report covers:
- A detailed and extensive description of the market with key analyst information.
- An exhaustive analysis of the macro and micro factors that influence the market guided by key recommendations.
- Analysis of regional regulations and other government policies that affect the global market for women’s health diagnosis.
- Knowledge about the market determinants that are stimulating the global market for women’s health diagnosis.
- Detailed and extensive market segments with regional distribution of expected revenues.
- Extensive profiles and recent developments of market players.
The key factors that contribute to the growth of the global market for women’s health diagnosis are the increasing incidence of chronic and lifestyle-related disorders in women, the increase in the number of diagnostic imaging centers and private diagnosis , the increasing prevalence of infectious diseases and the increasing adoption of point of care and rapid diagnostic tests.
According to the World Health Organization (WHO), around 36.9 million people worldwide live with HIV and almost 23.3 million people have received antiretroviral treatment in 2018. In addition, the increased incidence of Chronic disorders such as breast cancer have increased the need for health. diagnosis in women.
Breast cancer is one of the most common types of cancer among women worldwide. According to the Breast Cancer Research Foundation, in 2018, breast cancer represents one in four of all cancers in women worldwide; while almost one in eight women in the US is expected. UU. develop invasive breast cancer during the course of your life.
According to the American Cancer Society, in 2019, it is projected to diagnose about 268,600 new cases of invasive breast cancer in women in the US. UU. Such an event broadens the scope for the growth of the global market for women’s health diagnosis. In addition to this, government support initiatives and health organizations and growing awareness about fertility tests have also played a vital role in the growth of the global market.
However, the lack of qualified laboratory personnel and the high cost of imaging procedures and diagnostic systems are the key factors that limit market growth.
The global market for women’s health diagnosis is segmented according to the application and the end user. According to the applications, prenatal tests are expected to have an important participation due to the increase in the prevalence of prenatal diseases, the increase in health expenditure and the increase in maternal age. According to the end user, diagnostic centers and hospitals represented an important part in the market due to the large number of hospital visits.
Geographically, the global market for women’s health diagnosis is segmented in North America, Europe, Asia-Pacific and the rest of the world. North America contributes with a significant participation in the world market for women’s health diagnosis due to the growing demand for fertility test monitors, the increasing prevalence of cancer and the incidence of lifestyle-related disorders within the region. In addition, Asia-Pacific is expected to witness a considerable growth rate in the global market for women’s health diagnosis during the forecast period. The growth is credited by the growing awareness among women related to various health disorders and increases income proportionately.
Key players operating in the global women’s health diagnosis market include Abbott Laboratories, Inc., biomerieux SA, Becton, Dickson and Co., DIALAB Gmbh, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corp., Siemens AG, Quest Diagnostics Inc., and General Electric Co. The adoption of growth strategies such as mergers and acquisitions, product launches, partnerships and agreements are the key strategies of the main market players.
For example, in January 2017, Abbott Laboratories, Inc. launched a biomedical immunization machine, such as the Alinityci series diagnostic systems. The Alinityci series is easy to use due to the compact size and scalable systems to maximize efficiency and performance. It allows hospitals and laboratories to achieve better health care performance.
Key topics covered:
1. Summary of the report
1.1. Research methods and tools
1.2. Market breakdown
1.2.1 By segments
1.2.2. By geography
1.2.3 By interested parties
2. Market description and prospects
2.1. Scope of the report
2.2. Analyst analysis and current market trends
2.2.1. Key results
2.3. Rules and Regulations
3. Competitive landscape
3.1. Company stock analysis
3.2. Key Strategy Analysis
3.3. Key company analysis
3.3.1 General Electric Co.
3.3.2. Abbott Laboratories, Inc.
3.3.3. Siemens AG
3.3.4. Becton, Dickinson and Co.
3.3.5 Quest Diagnostics Inc.
4. Market determinants
5. Market segmentation
5.1. Global market for women’s health diagnosis by application
5.1.1 Breast cancer test
5.1.2. Cervical Cancer Test
5.1.3. Pregnancy and fertility tests
5.1.4. Ovarian cancer test
5.1.5. Infectious disease tests
5.1.6. Ultrasound tests
5.1.7. Sexually transmitted disease test
5.1.8. Others (osteoporosis tests and prenatal genetic tests)
5.2. Global market for women’s health diagnosis by end user
5.2.1. Diagnostic and imaging centers
5.2.2. Hospitals and clinics
5.2.3. Home care
6. Regional analysis
6.1. North America
6.2.1. United Kingdom
6.2.6. The rest of Europe
6.3. Pacific Asia
6.3.4. Rest of Asia-Pacific
6.4. Rest of the world
7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.2. Becton, Dickson and Co.
7.3. bioMerieux S.A.
7.4. DIALAB GmbH
7.5. EKF Diagnostics Holdings PLC
7.6. F. Hoffmann-La Roche Ltd.
7.7. Fujifilm Holdings Corp.
7.8. General Electric Co.
7.9. GenMark Diagnostics, Inc.
7.10. Hologic, Inc.
7.11. Koninklijke Philips N.V.
7.12. Luminex Corp.
7.13. Nova Biomedical Pte. Limited.
7.14 PerkinElmer Inc.
7.15. QIAGEN N.V.
7.16. Quest Diagnostics Inc.
7.17. Siemens AG
7.18. Somagen Diagnostics Inc.
7.19. Thermo Fisher Scientific Inc.
7.20. Trinity Biotech PLC
For more information on this report, visit https://www.researchandmarkets.com/r/s8memd
Research and Markets also offers personalized research services that provide focused, comprehensive and personalized research.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900